KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $111.2 million.

  • Halozyme Therapeutics' Accumulated Expenses rose 1531.47% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 1531.47%. This contributed to the annual value of $128.9 million for FY2024, which is 2798.33% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Accumulated Expenses stood at $111.2 million for Q3 2025, which was up 1531.47% from $115.6 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Accumulated Expenses ranged from a high of $130.3 million in Q1 2025 and a low of $16.1 million during Q1 2021
  • Its 5-year average for Accumulated Expenses is $81.9 million, with a median of $96.4 million in 2024.
  • In the last 5 years, Halozyme Therapeutics' Accumulated Expenses plummeted by 3995.75% in 2021 and then soared by 33634.43% in 2022.
  • Halozyme Therapeutics' Accumulated Expenses (Quarter) stood at $24.4 million in 2021, then skyrocketed by 308.17% to $99.8 million in 2022, then increased by 0.92% to $100.7 million in 2023, then increased by 27.98% to $128.9 million in 2024, then dropped by 13.71% to $111.2 million in 2025.
  • Its last three reported values are $111.2 million in Q3 2025, $115.6 million for Q2 2025, and $130.3 million during Q1 2025.